ValiRx PLC Directorate Change

RNS Number : 6828I

ValiRx PLC

18 October 2024

 

ValiRx plc

 

("ValiRx" or the "Company")

 

Directorate Change

 

ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces the resignation of Martin Lampshire as a Non-Executive Director of the Company, effective from 18 October 2024.

 

Martin has decided to step down from the Board of ValiRx to concentrate on his other commitments.

 

During Martin's four year tenure as a ValiRx Non-Executive Director, he has made significant contributions to the development of the strategy and helped the Company build relationships with various City stakeholders.

 

Martin Gouldstone, Chairman of ValiRx commented "I would very much like to extend my sincere appreciation to Martin for his contributions whilst serving as Non Executive Director for ValiRx. He has been a great support of the Company during the short time that both myself and Mark Eccleston have been in our respective roles and has helped with identifying further cost reductions that ValiRx can make in the short term to allow us to concentrate on the Company's longer term commercial and strategic objectives."

 

Mark Eccleston, CEO of ValiRx commented " I too would like to thank Martin for his contribution and guidance in my limited tenure to date. As ValiRx moves forward the board will evolve to bring more commercial and clinical development experience which, alongside cost savings in the range of  £100, 000 we have identified, will focus the Company on building its therapeutic pipeline."

 

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

 

ValiRx plc   Dr Mark Eccleston, CEO	Tel: [phone] www.valirx.com [e-mail]
V Formation (Public Relations)   Lucy Wharton - Senior PR Executive Sue Carr - Director	[phone] www.vformation.biz   [e-mail] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser)   Liam Murray/Ludovico Lazzaretti	Tel: [phone]
Shard Capital Partners LLP (Sole Broker)   Damon Heath	Tel: [phone]
BioRep srl Daniela Sica (BU Biotech CCO)	Tel: [phone]
Sapio Group Valentina Semeraro (Head of Media Relations)	Tel: [phone]

 

 

Notes for Editors

 

About ValiRx

 

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BOAGPGCCUUPCPUM